Cancer Family
Mesenchymal Cell Neoplasm
CI-CAN-00000027Explore in graph →
Non-malignant413 active trials10 approved drugs208 evidence items
- NCIt
- C7059
Loading cancer entity…
Cancer Family
CI-CAN-00000027Explore in graph →
Clinical trials
1,848 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | recruiting | Phase 3 | 800 | GlaxoSmithKlineINDUSTRY | 15 | Sep 24, 2026 | clinicaltrials |
| NCT06422806 | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | recruiting | Phase 3 | 365 | National Cancer Institute (NCI)NIH | 3 | Sep 22, 2026 |
| clinicaltrials |
| NCT07823491 | Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall | not yet recruiting | Phase 3 | 228 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03180268 | Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | recruiting | Phase 3 | 163 | NRG OncologyOTHER | 5 | Sep 10, 2026 | clinicaltrials |
| NCT04031677 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma(STRASS2) | recruiting | Phase 3 | 250 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Sep 10, 2026 | clinicaltrials |
| NCT02567435 | Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | active not recruiting | Phase 3 | 325 | National Cancer Institute (NCI)NIH | 5 | Aug 28, 2026 | clinicaltrials |
| NCT05235165 | Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | recruiting | Phase 3 | 62 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT05304585 | Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | recruiting | Phase 3 | 205 | Children's Oncology GroupNETWORK | 4 | Aug 25, 2026 | clinicaltrials |
| NCT07466316 | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) | recruiting | Phase 3 | 342 | Children's Oncology GroupNETWORK | 2 | Aug 25, 2026 | clinicaltrials |
| NCT05364008 | FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea(FRIEND) | active not recruiting | Phase 3 | 33 | Yale UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04994132 | A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma | active not recruiting | Phase 3 | 113 | Children's Oncology GroupNETWORK | 5 | Jul 30, 2026 | clinicaltrials |
| NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | recruiting | Phase 3 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07661342 | DEPART Study at Yale(Dupuytren's) | not yet recruiting | Phase 3 | 158 | Yale UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06088290 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)(SaLuDo) | active not recruiting | Phase 3 | 469 | PharmaMarINDUSTRY | 12 | Jun 18, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT07379047 | Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)(GISTAR-1) | recruiting | Phase 2 / Phase 3 | 255 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Jun 10, 2026 | clinicaltrials |
| NCT04871282 | A Study of AL102 in Patients With Progressing Desmoid Tumors(RINGSIDE) | active not recruiting | Phase 2 / Phase 3 | 198 | Immunome, Inc.INDUSTRY | 11 | Jun 8, 2026 | clinicaltrials |
| NCT05804045 | Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) | active not recruiting | Phase 3 | 94 | Abbisko Therapeutics Co, LtdINDUSTRY | 7 | May 4, 2026 | clinicaltrials |
| NCT07378098 | to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia | recruiting | Phase 3 | 254 | JW PharmaceuticalINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT06935409 | Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | active not recruiting | Phase 3 | 117 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05059262 | Study of Vimseltinib for Tenosynovial Giant Cell Tumor(MOTION) | active not recruiting | Phase 3 | 123 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Mar 20, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib(INTRIGUE) | active not recruiting | Phase 3 | 453 | Deciphera Pharmaceuticals, LLCINDUSTRY | 22 | Feb 5, 2026 | clinicaltrials |
| NCT06671548 | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | recruiting | Phase 3 | 120 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05734105 | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib(INSIGHT) | active not recruiting | Phase 3 | 54 | Deciphera Pharmaceuticals, LLCINDUSTRY | 15 | Dec 17, 2025 | clinicaltrials |
| NCT05862272 | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | recruiting | Phase 3 | 1,000 | Sumitomo Pharma Switzerland GmbHINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06836492 | A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors. | recruiting | Phase 3 | 300 | Yizhuo ZhangOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02923011 | Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas | recruiting | Phase 3 | 56 | Matthew BucknorOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03948789 | Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy | active not recruiting | Phase 3 | 127 | Krankenhaus NordwestOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06669013 | Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas(FollowTheDIN) | recruiting | Phase 3 | 40 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03507010 | Ledderhose Disease: Radiotherapy or Not?(LedRad) | active not recruiting | Phase 3 | 84 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05328258 | Use of GnRHa During Chemotherapy for Fertility Protection(ProFertil) | recruiting | Phase 3 | 500 | Kenny Rodriguez-WallbergOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05970900 | Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST(PIRKER) | not yet recruiting | Phase 3 | 23 | Fujian Medical University Union HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials